Neoclease develops custom nucleases for gene editing by leveraging generative AI and synthetic biology. Their technology engineers precise, efficient gene-specific nucleases designed for therapeutic editing in hard-to-reach tissues. This platform aims to improve the safety and efficacy of precision medicine treatments for genetic disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Developing gene-editing therapies faces challenges with nuclease specificity and efficiency, particularly in targeting difficult-to-access tissues. This limits the potential for precise therapeutic interventions in genetic disorders and complex diseases.
Solution
Neoclease engineers gene-specific nucleases utilizing a generative AI platform to enhance precision and efficiency in therapeutic gene editing. Their technology focuses on developing miniaturized, highly accurate enzymes capable of targeting specific genes and diseases, thereby enabling novel approaches to precision medicine. This platform facilitates the development of advanced therapies for a range of genetic disorders and complex conditions. The company's initial focus includes developing an editor for LRRK2 in Parkinson's disease to potentially slow or halt its progression.
Target Audience
Neoclease targets pharmaceutical companies and biotechnology firms engaged in the development of gene therapies for genetic disorders and complex diseases.
Features
- Generative AI-driven platform for custom nuclease design.
- Development of miniaturized, precise, and efficient gene-editing enzymes.
- Capability to target specific genes and diseases, including those in previously inaccessible tissues.
- Application in precision medicine for therapeutic gene editing.
- Focus on developing novel therapies for genetic disorders and complex diseases.
- Specific application development for targeting LRRK2 in Parkinson's disease.